The availability of new, innovative and specialist cancer drugs in Australia, with particular reference to:
- the timing and affordability of access for patients;
- the operation of the Pharmaceutical Benefits Advisory Committee and the Pharmaceutical Benefits Scheme in relation to such drugs, including the impact of delays in the approvals process for Australian patients;
- the impact on the quality of care available to cancer patients; and
- any related matters.